Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics (NQ: HZNP )

110.37 USD +0.88 (+0.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 24, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 888,540
Open 108.90
Bid (Size) 110.37 (4)
Ask (Size) 115.00 (2)
Prev. Close 109.49
Today's Range 108.64 - 110.86
52wk Range 66.41 - 111.70
Shares Outstanding 225,893,375
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline
- Milestone Achieved by HemoShear in Exclusive Drug Discovery Collaboration - 
From PR Newswire
Horizon Therapeutics plc Announces Agenda for Virtual R&D Day for Investors and Analysts on Sept. 29, 2021
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the agenda for its virtual R&D Day for investors and analysts on Sept. 29, 2021. During the event, Horizon’s R&D leadership, executives and key... 
From Business Wire News Releases

Performance

YTD
+52.15%
+52.15%
1 Month
+1.21%
+1.21%
3 Month
+15.06%
+15.06%
6 Month
+32.96%
+32.96%
1 Year
+46.52%
+46.52%

More News

Read More
Horizon Therapeutics plc Announces Data Showing UPLIZNA® (inebilizumab-cdon) Also Produces Rapid and Sustained B-Cell Depletion in African Americans with Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Business Wire News Releases
Horizon Therapeutics plc Announces New Genetic Counselor Curated Algorithms and Next-Generation Sequencing Data as Winning Solutions of First-Ever Horizon Prize, Powered by MIT Solve, to Accelerate Ra
From Business Wire News Releases
Horizon Therapeutics plc Named One of the 2021 Best Workplaces for Women™ by Fortune and Great Place to Work®
From Business Wire News Releases
Horizon Therapeutics plc Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Chronic (Inactive) Thyroid Eye Disease (TED)
From Business Wire News Releases
Horizon Therapeutics plc Named One of PEOPLE’s 100 Companies That Care®
From Business Wire News Releases
Horizon Therapeutics plc to Participate in Upcoming Conferences
From Business Wire News Releases
Notable Tuesday Option Activity: FSLY, HZNP, OCUL
Tags Stocks
From Market News Video
9 Health Care Stocks Showing Unusual Options Activity In Today's Session
Tags TAK PFE Options
From Benzinga
First Week of October 15th Options Trading For Horizon Therapeutics
Tags Stocks
From Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.